BIOAGE LABS INC. O.N. Aktie

BioAge Labs shares fell 51.9% in premarket trading after Novo Nordisk’s IL‑6 inhibitor ziltivekimab showed no reduced risk of major cardiovascular events versus placebo in the phase‑3 ZEUS trial. The result calls into question the underlying assumption that blocking upstream inflammatory pathways confers cardiovascular benefit and directly weakens the prospects for BioAge’s oral NLRP3 inhibitor BGE‑102 in the ongoing phase‑2 QUELL‑CV study. Investors have markedly downgraded the likelihood of a positive outcome for BGE‑102 after a well‑funded, thematically related program failed. » Altro su de.investing.com

BioAge has dosed the first participant in a randomized, double-blind, placebo-controlled phase‑2 dose-finding study of the oral NLRP3 inhibitor BGE-102. The QUELL-CV study aims to determine the optimal dose for phase‑3 development in participants with increased cardiovascular risk; topline data are expected in the second half of 2026. BGE-102 was developed from a compound identified using HitGen’s DNA-Encoded-Library (DEL) technology platform; phase‑1 data showed a reduction in high-sensitivity CRP. The partnership between HitGen and BioAge began in 2021 and underscores the application of HitGen’s DEL platform. » Altro su de.investing.com

Shares of Bioage Labs rose to a 52-week high of $25.8 and are currently trading around $25.53, giving a market capitalization of about $1.12 billion. Analysts say the stock is near or above fair‑value estimates despite strong price gains (up 486% last year), while the RSI points to overbought conditions. At the same time, BioAge Labs is dosing the first participant in a Phase‑2 trial of BGE‑102 after positive Phase‑1 results showing a reduction in an inflammation marker; Roth/MKM and Jefferies have reaffirmed buy ratings. » Altro su de.investing.com